Opioid-induced proinflammatory glial activation modulates wide-ranging aspects of opioid pharmacology including: opposition of acute and chronic opioid analgesia, opioid analgesic tolerance, opioidinduced hyperalgesia, development of opioid dependence, opioid reward, and opioid respiratory depression. However, the mechanism(s) contributing to opioid-induced proinflammatory actions remains unresolved. The potential involvement of toll-like receptor 4 (TLR4) was examined using in vitro, in vivo, and in silico techniques. Morphine non-stereoselectively induced TLR4 signaling in vitro, blocked by a classical TLR4 antagonist and non-stereoselectively by naloxone. Pharmacological blockade of TLR4 signaling in vivo potentiated acute intrathecal morphine analgesia, attenuated development of analgesic tolerance, hyperalgesia, and opioid withdrawal behaviors. TLR4 opposition to opioid actions was supported by morphine treatment of TLR4 knockout mice, which revealed a significant threefold leftward shift in the analgesia dose response function, versus wildtype mice. A range of structurally diverse clinically-employed opioid analgesics was found to be capable of activating TLR4 signaling in vitro. Selectivity in the response was identified since morphine-3-glucuronide, a morphine metabolite with no opioid receptor activity, displayed significant TLR4 activity, whilst the opioid receptor active metabolite, morphine-6-glucuronide, was devoid of such properties. In silico docking simulations revealed ligands bound preferentially to the LPS binding pocket of MD-2 rather than TLR4. An in silico to in vitro prediction model was built and tested with substantial accuracy. These data provide evidence that select opioids may non-stereoselectively influence TLR4 signaling and have behavioral consequences resulting, in part, via TLR4 signaling.
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Introduction
Recent evidence indicates that glia can exhibit proinflammatory responses to opioids, contributing to a reduced opioid analgesia and development of tolerance and dependence, albeit by a previously uncharacterized mechanism (Hutchinson et al., 2007; Watkins et al., 2005) . In vivo opioid-induced proinflammatory glial activation has been inferred from: (a) morphine-induced upregulation of microglial (Cui et al., 2008; Hutchinson et al., 2009 ) and astrocytic (Hutchinson et al., 2009; Song and Zhao, 2001 ) activation markers, (b) morphine-induced upregulation and/or release of proinflammatory cytokines (Hutchinson et al., 2008a (Hutchinson et al., ,b,c, 2009 Johnston et al., 2004; Raghavendra et al., 2002 Raghavendra et al., , 2004 , (c) enhanced morphine analgesia by coadministering the microglial attenuators minocycline (Cui et al., 2008; Hutchinson et al., 2008a,b,c) or AV411 (Hutchinson et al., 2009) , and the astrocyte inhibitor fluorocitrate (Song and Zhao, 2001), (d) enhanced morphine analgesia by blocking proinflammatory cytokine actions (Hutchinson et al., 2008a,b,c; Shavit et al., 2005) , and (e) opioid-induced selective activation of microglial p38 MAPK and associated enhanced morphine analgesia (Cui et al., 2006) . As such, opioid-induced proinflammatory glial activation is characterized by a cellular phenotype of enhanced reactivity and propensity to proinflammation in response to exposure of glia to opioids.
